|
TODAY’S TOP ALERT! | MAIA Biotechnology (NYSE: MAIA) | | 👉 MAIA is TODAY’S #1 ALERT 👈 | Good afternoon, Jeff Bishop here again. | On the surface, tensions are hotter than ever between Israel, Iran, and the U.S. | President Trump says Ayatollah Khamenei is an “easy target,” and the Ayatollah promises “irreparable damage” if the U.S. joins the fight. | Remarkably, the markets aren’t buying it. | The odds of a nuclear deal are rising in betting markets, and oil prices still haven’t passed their high from this January. | Retail investors are participating in this market at record highs. And where are they looking?
“Penny stocks, a proxy for retail activity, reflected a record 47.4% of the total market volume on Thursday, according to Goldman Sachs.” [emphasis added] | Penny stocks are where it’s at, folks. | This morning, I shot you a “tactical trade” idea on a small biopharma stock that I thought was at a level that “deserves a good, hard look.” | I hope you looked, because here’s what happened: |  | *Note: Trading is hard, results not guaranteed and should not be expected to be replicated typically. |
| It’s floating around 13% right now, and I’m hoping we’ll see it break at least 20% before the day’s through. | It certainly hasn’t hurt that the company let fly big news this morning about a “clinical master supply agreement with Roche for future studies investigating the combination of MAIA’s telomere-targeting agent ateganosine (THIO), sequenced with Roche’s checkpoint inhibitor (CPI), atezolizumab (Tecentriq®), for the treatment of multiple hard-to-treat cancers.” | The two drugs were found to be “highly synergistic” in preclinical studies. | I had mentioned in my email this morning that clinical results like the ones MAIA has been seeing “can attract big pharma partnerships,” and I’d say Roche ($250+ billion market cap) fits the bill. | Pay close attention to see where MAIA goes from here! | To Your Success, | | P.S. Don't miss out on our MOBILE ALERTS! Some of these alerts have rocketed past the MOON 🌝. Simply text “RAGE” to 1-(888) 487-1534 📲. | *Disclosure: By texting “RAGE” to 1-(888) 487-1534, you agree to receive promotional messages sent via an autodialer. You also agree to the terms of service and privacy policy. This agreement isn’t a condition of any purchase. Message frequency varies. Message and data rates may apply. Reply STOP to opt out; HELP for more information. | | | Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull | | DISCLAIMER: This entity is owned by Ragingbull.com, LLC ("RagingBull"). To more fully understand any RB subscription, website, application or other service, please review our full disclaimer located at https://ragingbull.com/disclaimer. | We are disseminating this report on behalf of Sherwood Ventures (SV). Sherwood’s full disclaimer is found here: https://bullseyealerts.com/disclaimer/ | Just so you know, what you're reading is curated content for which we (SV) have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.” | Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we currently have received thirty five thousand thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on June 18, 2025. Before this, we received twenty five thousand thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a two day marketing program starting on May 1, 2025. Before this, we received fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on April 23, 2025. Prior to that, we received fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on March 20, 2025. Before this, we received fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on February 27, 2025. Prior to that, we received thirty five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on January 7, 2025, and we also received fifteen thousand dollars (cash) from Legends Media for advertising MAIA Biotechnology, Inc for a one day marketing program on December 16, 2024, and we received twenty-five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on November 7, 2024, and also twenty-five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on July 9, 2024 and also fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on June 13, 2024. Previously, we received twelve thousand five hundred dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on June 7, 2024. Also, we were paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc for a one day marketing program on March 6, 2024. We were also previously paid fourteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on November 15 through November 18, 2023, and also fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on October 12 through October 13, 2023. These amounts were paid by someone else not connected to MAIA Biotechnology, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case. | Now, diving right into MAIA Biotechnology, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r. | Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now. | Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, | Neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization. | So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture. |
|
|
|